2021 |
01/12 | 7,405 | 7,635 | 7,381 | 7,606 | +3.38% | 1,594,100 | 2兆2556億 | +2.38% |
01/08 | 7,330 | 7,360 | 7,256 | 7,357 | +1.14% | 889,600 | 2兆1818億 | -1.01% |
01/07 | 7,342 | 7,360 | 7,245 | 7,274 | +0.26% | 847,700 | 2兆1572億 | -2.36% |
01/06 | 7,210 | 7,271 | 7,190 | 7,255 | +0.15% | 514,000 | 2兆1515億 | -2.89% |
01/05 | 7,339 | 7,347 | 7,214 | 7,244 | -0.71% | 726,600 | 2兆1483億 | -3.37% |
01/04 | 7,368 | 7,368 | 7,257 | 7,296 | -1.03% | 422,000 | 2兆1637億 | -2.95% |
2020 |
12/30 | 7,411 | 7,439 | 7,358 | 7,372 | -0.49% | 678,500 | 2兆1862億 | -2.22% |
12/29 | 7,298 | 7,436 | 7,270 | 7,408 | +2.33% | 802,800 | 2兆1969億 | -1.92% |
12/28 | 7,230 | 7,285 | 7,176 | 7,239 | +0.37% | 560,600 | 2兆1468億 | -4.36% |
12/25 | 7,227 | 7,227 | 7,168 | 7,212 | -0.03% | 567,400 | 2兆1388億 | -4.97% |
12/24 | 7,195 | 7,274 | 7,144 | 7,214 | -0.15% | 738,600 | 2兆1394億 | -5.23% |
12/23 | 7,283 | 7,290 | 7,218 | 7,225 | -0.89% | 586,600 | 2兆1426億 | -5.33% |
12/22 | 7,279 | 7,334 | 7,258 | 7,290 | -1.22% | 641,900 | 2兆1619億 | -4.72% |
12/21 | 7,398 | 7,398 | 7,294 | 7,380 | -0.54% | 851,700 | 2兆1886億 | -3.81% |
12/18 | 7,500 | 7,534 | 7,413 | 7,420 | -1.19% | 1,104,600 | 2兆2005億 | -3.59% |
12/17 | 7,548 | 7,585 | 7,509 | 7,509 | -0.67% | 543,800 | 2兆2269億 | -2.72% |
12/16 | 7,642 | 7,642 | 7,527 | 7,560 | -0.21% | 598,900 | 2兆2420億 | -2.26% |
12/15 | 7,600 | 7,610 | 7,530 | 7,576 | -0.97% | 735,100 | 2兆2467億 | -2.13% |
12/14 | 7,568 | 7,660 | 7,567 | 7,650 | +0.38% | 705,400 | 2兆2687億 | -1.3% |
12/11 | 7,653 | 7,730 | 7,521 | 7,621 | -1.05% | 1,314,400 | 2兆2601億 | -2.97% |
12/10 | 12:30 アデュカヌマブ、日本において新薬承認を申請 |
12/10 | 7,492 | 7,841 | 7,452 | 7,702 | +2.07% | 2,116,300 | 2兆2841億 | -3.06% |
12/09 | 7,482 | 7,577 | 7,481 | 7,546 | +0.88% | 1,351,700 | 2兆2378億 | -5.34% |
12/08 | 7,598 | 7,598 | 7,476 | 7,480 | -1.77% | 1,272,500 | 2兆2183億 | -6.46% |
12/07 | 7,725 | 7,740 | 7,573 | 7,615 | -0.81% | 819,200 | 2兆2583億 | -5.06% |
12/04 | 7,690 | 7,702 | 7,647 | 7,677 | -0.17% | 621,400 | 2兆2767億 | -4.65% |
12/03 | 7,749 | 7,749 | 7,631 | 7,690 | -1.21% | 1,000,000 | 2兆2805億 | -4.85% |
12/02 | 7,848 | 7,864 | 7,771 | 7,784 | -0.42% | 887,700 | 2兆3084億 | -4.04% |
12/01 | 7,888 | 7,982 | 7,801 | 7,817 | -0.89% | 916,300 | 2兆3182億 | -3.96% |
11/30 | 7,862 | 7,902 | 7,735 | 7,887 | +1.34% | 2,049,200 | 2兆3390億 | -3.33% |
11/27 | 7,816 | 7,827 | 7,746 | 7,783 | -0.46% | 1,096,600 | 2兆3081億 | -4.83% |
11/26 | 7,790 | 7,825 | 7,745 | 7,819 | +1.16% | 732,400 | 2兆3188億 | -4.76% |
11/25 | 7,847 | 7,876 | 7,721 | 7,729 | -0.78% | 969,500 | 2兆2921億 | -6.22% |
11/24 | 7,818 | 7,840 | 7,752 | 7,790 | +0.62% | 890,500 | 2兆3102億 | -5.93% |
11/20 | 7,797 | 7,797 | 7,718 | 7,742 | -0.72% | 670,100 | 2兆2960億 | -6.85% |
11/19 | 7,699 | 7,798 | 7,637 | 7,798 | +1.29% | 1,102,800 | 2兆3126億 | -6.64% |
11/18 | 7,747 | 7,786 | 7,644 | 7,699 | -0.16% | 992,900 | 2兆2832億 | -8.33% |
11/17 | 7,800 | 7,807 | 7,684 | 7,711 | -1.31% | 1,296,100 | 2兆2868億 | -8.76% |
11/16 | 7,980 | 7,986 | 7,811 | 7,813 | -2.13% | 1,457,600 | 2兆3170億 | -8.24% |
11/13 | 8,000 | 8,042 | 7,911 | 7,983 | -0.09% | 1,158,800 | 2兆3674億 | -6.93% |
11/12 | 8,010 | 8,060 | 7,919 | 7,990 | +1.06% | 1,383,300 | 2兆3695億 | -7.54% |
11/11 | 7,766 | 7,944 | 7,737 | 7,906 | +2.41% | 1,929,400 | 2兆3446億 | -9.14% |
11/10 | 7,887 | 7,899 | 7,660 | 7,720 | -1.27% | 2,813,400 | 2兆2894億 | -12.02% |
11/09 | 7,770 | 7,917 | 7,558 | 7,819 | -23.64% | 5,154,900 | 2兆3188億 | -11.69% |
11/07 | 10:15 アルツハイマー病におけるアデュカヌマブに関するFDA諮問委員会について |
11/06 | 10,540 | 10,900 | 10,200 | 10,240 | +3.7% | 4,587,200 | 3兆368億 | +14.76% |
11/05 | 15:30 2020年度第2四半期決算説明会資料 |
11/05 | 12:30 2021年3月期第2四半期決算短信参考資料[IFRS] |
11/05 | 12:30 2021年3月期第2四半期決算短信[IFRS](連結) |
11/05 | 9,875 | 9,875 | 9,875 | 9,875 | +17.91% | 186,100 | 2兆9285億 | +10.99% |
11/04 | 8,330 | 8,442 | 8,194 | 8,375 | +2.38% | 782,500 | 2兆4837億 | -5.74% |
11/02 | 8,070 | 8,220 | 8,070 | 8,180 | +1.12% | 633,900 | 2兆4259億 | -8.46% |
10/30 | 20:00 アデュカヌマブ、アルツハイマー病治療薬として、欧州医薬品庁への販売承認申請が受理 |
10/30 | 8,307 | 8,379 | 8,076 | 8,089 | -3.3% | 1,124,300 | 2兆3989億 | -10.01% |
10/29 | 8,345 | 8,468 | 8,345 | 8,365 | -0.82% | 439,100 | 2兆4807億 | -7.5% |
10/28 | 8,440 | 8,488 | 8,393 | 8,434 | -0.28% | 488,000 | 2兆5012億 | -7.22% |
10/27 | 8,384 | 8,470 | 8,328 | 8,458 | +0.08% | 441,500 | 2兆5083億 | -7.42% |
10/26 | 8,439 | 8,494 | 8,390 | 8,451 | +1.45% | 449,100 | 2兆5062億 | -7.91% |
10/23 | 8,348 | 8,387 | 8,280 | 8,330 | -0.3% | 494,600 | 2兆4704億 | -9.61% |
10/22 | 8,559 | 8,559 | 8,342 | 8,355 | -2.51% | 521,400 | 2兆4778億 | -9.73% |
10/21 | 20:30 アデュカヌマブの欧州医薬品庁への販売承認申請の提出について |
10/21 | 8,590 | 8,603 | 8,518 | 8,570 | -0.79% | 452,500 | 2兆5415億 | -7.78% |
10/20 | 8,590 | 8,677 | 8,546 | 8,638 | -0.64% | 595,300 | 2兆5617億 | -7.33% |
10/19 | 8,590 | 8,698 | 8,566 | 8,694 | +1.66% | 687,400 | 2兆5783億 | -6.97% |
10/16 | 8,712 | 8,755 | 8,536 | 8,552 | -2.69% | 728,100 | 2兆5362億 | -8.69% |
10/15 | 8,875 | 8,904 | 8,731 | 8,788 | -1.71% | 727,400 | 2兆6062億 | -6.46% |
10/14 | 8,953 | 8,980 | 8,890 | 8,941 | -0.62% | 652,600 | 2兆6516億 | -5.07% |
10/13 | 9,267 | 9,282 | 8,953 | 8,997 | -3.29% | 1,013,500 | 2兆6682億 | -4.67% |
10/12 | 9,350 | 9,400 | 9,239 | 9,303 | -0.77% | 548,300 | 2兆7589億 | -1.66% |
10/09 | 9,591 | 9,592 | 9,328 | 9,375 | -2.49% | 1,029,400 | 2兆7803億 | -0.97% |
10/08 | 9,534 | 9,668 | 9,482 | 9,614 | +1.74% | 596,800 | 2兆8511億 | +1.52% |
10/07 | 9,633 | 9,680 | 9,416 | 9,450 | -3.2% | 790,300 | 2兆8025億 | -0.06% |
10/06 | 9,686 | 9,824 | 9,683 | 9,762 | +0.71% | 455,000 | 2兆8950億 | +3.38% |
10/05 | 9,645 | 9,780 | 9,600 | 9,693 | +1.57% | 658,400 | 2兆8746億 | +2.8% |
10/02 | 9,645 | 9,675 | 9,490 | 9,543 | -0.43% | 617,800 | 2兆8301億 | +1.33% |
09/30 | 9,625 | 9,691 | 9,551 | 9,584 | +0.13% | 929,300 | 2兆8422億 | +1.83% |
09/29 | 9,631 | 9,674 | 9,433 | 9,572 | -0.83% | 542,400 | 2兆8387億 | +1.79% |
09/28 | 9,599 | 9,660 | 9,518 | 9,652 | +1.37% | 692,900 | 2兆8624億 | +2.77% |
09/25 | 9,465 | 9,577 | 9,465 | 9,522 | +0.96% | 582,100 | 2兆8239億 | +1.5% |
09/24 | 9,523 | 9,540 | 9,383 | 9,431 | -1.23% | 552,600 | 2兆7969億 | +0.58% |
09/23 | 9,542 | 9,597 | 9,489 | 9,548 | -0.2% | 662,400 | 2兆8316億 | +1.83% |
09/18 | 9,500 | 9,582 | 9,441 | 9,567 | +0.78% | 777,400 | 2兆8372億 | +2% |
09/17 | 9,371 | 9,493 | 9,347 | 9,493 | +0.61% | 436,400 | 2兆8153億 | +1.17% |
09/16 | 9,317 | 9,447 | 9,295 | 9,435 | +1.17% | 511,700 | 2兆7981億 | +0.59% |
09/15 | 9,310 | 9,332 | 9,252 | 9,326 | +0.63% | 410,500 | 2兆7657億 | -0.51% |
09/14 | 9,242 | 9,295 | 9,229 | 9,268 | -0.13% | 399,700 | 2兆7485億 | -1.34% |
09/11 | 9,336 | 9,336 | 9,065 | 9,280 | +0.53% | 1,098,900 | 2兆7521億 | -0.94% |
09/10 | 9,294 | 9,317 | 9,181 | 9,231 | +0.2% | 588,800 | 2兆7376億 | -1.15% |
09/09 | 9,213 | 9,294 | 9,132 | 9,213 | -0.7% | 658,300 | 2兆7322億 | -1.1% |
09/08 | 9,375 | 9,458 | 9,200 | 9,278 | -1.35% | 713,900 | 2兆7515億 | -0.2% |
09/07 | 9,500 | 9,556 | 9,403 | 9,405 | -0.14% | 438,500 | 2兆7892億 | +1.38% |
09/04 | 9,399 | 9,487 | 9,381 | 9,418 | -1.37% | 537,000 | 2兆7930億 | +1.93% |
09/03 | 9,527 | 9,587 | 9,484 | 9,549 | +0.77% | 575,000 | 2兆8319億 | +3.62% |
09/02 | 9,365 | 9,500 | 9,340 | 9,476 | +0.42% | 546,200 | 2兆8102億 | +3.17% |
09/01 | 9,415 | 9,511 | 9,376 | 9,436 | +1.85% | 693,000 | 2兆7984億 | +3.05% |
08/31 | 9,290 | 9,342 | 9,181 | 9,265 | +1.37% | 723,600 | 2兆7476億 | +1.49% |
08/28 | 9,300 | 9,338 | 8,888 | 9,140 | -2.75% | 844,100 | 2兆7106億 | +0.34% |
08/27 | 9,401 | 9,416 | 9,350 | 9,398 | -0.12% | 296,900 | 2兆7871億 | +3.34% |
08/26 | 9,412 | 9,452 | 9,372 | 9,409 | -0.05% | 331,100 | 2兆7903億 | +3.85% |
08/25 | 9,440 | 9,503 | 9,365 | 9,414 | +0.41% | 555,300 | 2兆7918億 | +4.32% |
08/24 | 9,292 | 9,385 | 9,276 | 9,376 | +1.06% | 408,100 | 2兆7806億 | +4.4% |
08/21 | 9,364 | 9,396 | 9,266 | 9,278 | -0.87% | 712,000 | 2兆7515億 | +3.73% |
08/20 | 9,315 | 9,424 | 9,295 | 9,359 | -0.75% | 616,600 | 2兆7755億 | +4.95% |
08/19 | 9,370 | 9,485 | 9,356 | 9,430 | +0.14% | 792,100 | 2兆7966億 | +6.09% |
08/18 | 9,620 | 9,627 | 9,417 | 9,417 | -2.02% | 962,600 | 2兆7927億 | +6.27% |
08/17 | 9,610 | 9,638 | 9,559 | 9,611 | -0.62% | 629,300 | 2兆8503億 | +8.7% |
08/14 | 9,542 | 9,707 | 9,461 | 9,671 | +2.74% | 1,062,500 | 2兆8680億 | +9.91% |
08/07 | 20:30 アデュカヌマブ、アルツハイマー病治療薬としてのBLA申請が米国FDAに受理され、優先審査に指定 |